GlobeNewswire by notified

Agillic joins partner Immeo in supporting the ‘Knæk Cancer’ (fight cancer) fundraising campaign

Share

Cancer affects one out of every three people in Denmark before the age of 75, making cancer something that touches most, if not every Dane. Whether as a patient, next of kin, friend, or colleague, we all know someone.

Every year, Kræften Bekæmpelse (The Danish Cancer Society) partners with TV2 for a national ‘Knæk Cancer’ fundraising campaign. For the past several years, Agillic partner Immeo has been supporting the campaign by organising a one-day tennis tournament as a fundraiser, bringing clients, partners, and friends together to contribute.

Ivan Beltoft, Partner at Immeo, explains:
“We have chosen to combine fun with sport and fundraising. We are very happy with the great support from our colleagues and clients who showed up with families and participated in our tennis tournament. We are very proud of this year’s collection and that we can contribute to the fight against cancer.”

And they should be, having raised no less than DKK 128,000 from the event. Agillic participated in the tournament and recognised the hard work and effort of Immeo, contributing an additional DKK 20,000. In total, DKK 148,000 is now going directly to Kræftens Bekæmpelse.

Earlier this year, Agillic welcomed Kræftens Bekæmpelse as a client, adding to a proud tradition of supporting charities and NGOs. Working with more than ten organisations across the Nordics, Agillic enables enterprise capabilities to help maintain the trust of their supporters and deliver on e.g., fundraising targets, whilst providing the best of security and privacy to leverage often highly sensitive data for their personalised massaging.

Says Agillic CEO Emre Gürsoy:
“We know first-hand from the charities and NGOs in our client portfolio how dependent they are on their supporters and fundraising activities. That is why we have always prioritised helping them in their important work, touching so many people every day. Being able to support both our partner Immeo and client Kræftens Bekæmpelse in this initiative is not only a privilege and a pleasure but an obligation. Those who can, must at least try to make a difference. As they say in the Knæk Cancer campaign: We can’t perform miracles – but we will try.”

Read more (in Danish) about Immeo’s fundraiser at https://www.immeo.dk/viden/knak-cancer-med-immeo-2023 and visit the official Knæk Cancer site for more information and to donate: https://knaek.cancer.dk/


For further information, please contact
Emre Gürsoy, CEO, Agillic A/S
+45 3078 4200
emre.gursoy@agillic.com

About Agillic A/S
Agillic (Nasdaq First North Growth Market Copenhagen: AGILC) is a Danish software company offering brands a platform through which they can work with data-driven insights and content to create, automate and send personalised communication to millions. Agillic is headquartered in Copenhagen, Denmark, with teams in Germany, Norway, and Romania.

Agillic A/S – Masnedøgade 22 – 2100 Copenhagen – Denmark – www.agillic.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

XPENG G9 Achieves a Five-Star 2023 Safety Rating from Euro NCAP6.12.2023 11:00:00 CET | Press release

The new XPENG G9, now on sale in Europe, received a five-star 2023 safety rating from Euro NCAPThis is XPENG's second five-star safety rating for an international model following the new P7 in October; and its first SUV obtained both Euro NCAP and C-NCAP five-star ratings AMSTERDAM, Dec. 06, 2023 (GLOBE NEWSWIRE) -- XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announces that the international model of their flagship electric SUV, XPENG G9, has received a five-star 2023 safety rating from Euro NCAP. Euro NCAP's five-star safety rating system aims to help consumers, their families and businesses compare vehicles more easily and identify the safest choice for their needs. The tests, which replicate real-life road danger scenarios, represent the European gold standard for comprehensive automotive safety testing. The rating recognises the XPENG G9's advanced body structure and comprehensive passive s

AS Tallink Grupp: Managers’ Transactions6.12.2023 11:00:00 CET | Press release

Person subject to the notification requirement Name: AS Infortar Position: Closely associated person (X) Legal person Person Discharging Managerial Responsibilities in Issuer Name: Hanschmidt, Ain Position: Member of the Supervisory Board Name: Pant, Eve Position: Member of the Supervisory Board Issuer: AS Tallink Grupp LEI: 529900QRMWAKKR3L9W75 Notification type: Initial Notification _____________________________________ Transaction date: 04.12.2023 Venue: Nasdaq OMX Tallinn Instrument type: Share ISIN: EE3100004466 Nature of the transaction: Acquisition Transaction details: (1): Volume: 105,178; Unit price: 0.68 EUR Aggregated transactions: (2): Volume: 105,178; Volume weighted average price: 0.68 EUR Anneli Simm Investor Relations Manager AS Tallink Grupp Sadama 5 10111 Tallinn E-mail Anneli.simm@tallink.ee

CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy6.12.2023 11:00:00 CET | Press release

ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA). Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology. The Phase 1 study (NCT06006585) is evaluating the safety, tolerability and pharmacokinetics of intravitreal single rising doses and multiple doses of BI 771716 as a potential treatment for GA. GA is a chronic and progressive, irreversible retinal disease that occurs in people with late-stage dry age-related macular degeneration (AMD) impacting the ability to see. More than 5 million people worldwide suffer from GA, of which more than 40% are legally blind. GA worsens with age, affecting 1 in 29 people above the age of 75 and 1 in 4 people above 90. Consequently, risi

ForFarmers N.V.: Approval competition authority for the acquisition of Piast Pasze Sp. z.o.o.6.12.2023 10:30:00 CET | Press release

Lochem, 6 December 2023 Approval competition authority for the acquisition of Piast Pasze Sp. z.o.o. Today, ForFarmers received approval from the Polish competition authority to acquire Piast Pasze Sp. z.o.o. ("Piast"). With this transaction, announced on 25 July 2023, ForFarmers/Tasomix's volume in Poland will expand by 410,000 tonnes, strengthening its position in the broiler sector in particular. Parties will work towards a closing of the acquisition. This transaction is in line with ForFarmers/Tasomix's strategic objectives to expand in the attractive Polish agricultural market. This press release contains information that qualifies as inside information within the meaning of Article 7 paragraph 1 of the EU Market Abuse Regulation. Note to the editor / For further information: Floor van Maaren, T: 06-29597746 Paweł Świerkula, Managing Director ForFarmers/Tasomix M + 48 510 22 00 22 • E: pawel.swierkula@tasomix.pl About ForFarmers ForFarmers N.V. is an international organisation tha